Oscillating positive expiratory pressure therapy may be performed poorly by children with cystic fibrosis

Tuesday, January 25th, 2022

This study was undertaken to evaluate the real-world performance of an oscillating positive expiratory pressure device when used by 21 pediatric patients with cystic fibrosis. Device performance was evaluated using a combined flow and pressure sensor; for subject safety, a disposable Vitalograph bacterial and viral filter was placed proximal to the sensor for each participant. Spirometry endpoints included FEV1 and FVC, and were measured using the Vitalograph In2itive handheld spirometer.